SG10201709400VA - Abiraterone acetate formulation - Google Patents
Abiraterone acetate formulationInfo
- Publication number
- SG10201709400VA SG10201709400VA SG10201709400VA SG10201709400VA SG10201709400VA SG 10201709400V A SG10201709400V A SG 10201709400VA SG 10201709400V A SG10201709400V A SG 10201709400VA SG 10201709400V A SG10201709400V A SG 10201709400VA SG 10201709400V A SG10201709400V A SG 10201709400VA
- Authority
- SG
- Singapore
- Prior art keywords
- abiraterone acetate
- acetate formulation
- formulation
- abiraterone
- acetate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C19/00—Other disintegrating devices or methods
- B02C19/16—Mills provided with vibrators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361789141P | 2013-03-15 | 2013-03-15 | |
| US201361883941P | 2013-09-27 | 2013-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201709400VA true SG10201709400VA (en) | 2018-01-30 |
Family
ID=51538105
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201709400VA SG10201709400VA (en) | 2013-03-15 | 2014-03-17 | Abiraterone acetate formulation |
| SG11201507681PA SG11201507681PA (en) | 2013-03-15 | 2014-03-17 | Abiraterone acetate formulation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507681PA SG11201507681PA (en) | 2013-03-15 | 2014-03-17 | Abiraterone acetate formulation |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20140287039A1 (fr) |
| EP (2) | EP2969227B1 (fr) |
| JP (4) | JP2016514707A (fr) |
| KR (3) | KR102121404B1 (fr) |
| CN (2) | CN110604721B (fr) |
| AU (2) | AU2014232508C1 (fr) |
| BR (1) | BR112015023629A8 (fr) |
| CA (1) | CA2907415C (fr) |
| CL (1) | CL2015002787A1 (fr) |
| ES (1) | ES2741800T3 (fr) |
| HK (2) | HK1219457A1 (fr) |
| IL (1) | IL241612B (fr) |
| MX (1) | MX2015013247A (fr) |
| NZ (1) | NZ712350A (fr) |
| PL (1) | PL2969227T3 (fr) |
| RU (1) | RU2732136C2 (fr) |
| SG (2) | SG10201709400VA (fr) |
| TW (2) | TWI686212B (fr) |
| WO (1) | WO2014145813A1 (fr) |
| ZA (1) | ZA201507209B (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2856316C (fr) | 2011-10-28 | 2020-07-28 | Global Dynamics Incorporated | Cable carene dirigeable |
| US20150246060A1 (en) | 2013-03-15 | 2015-09-03 | Iceutica Inc. | Abiraterone Acetate Formulation and Methods of Use |
| US20150157646A1 (en) | 2013-09-27 | 2015-06-11 | Iceutica Inc. | Abiraterone Steroid Formulation |
| EP3080141A1 (fr) * | 2013-12-12 | 2016-10-19 | Basf Se | Forme solide d'acétate d'abiratérone |
| WO2015114314A1 (fr) * | 2014-01-28 | 2015-08-06 | Cipla Limited | Composition pharmaceutique contenant de l'abiratérone |
| WO2016044701A1 (fr) * | 2014-09-18 | 2016-03-24 | Iceutica Inc. | Formulation d'acétate d'abiratérone et ses procédés d'utilisation |
| CN105616364B (zh) * | 2014-11-07 | 2018-11-02 | 深圳万乐药业有限公司 | 醋酸阿比特龙片及其制备方法 |
| DK3226843T3 (da) | 2014-12-05 | 2021-08-16 | Aragon Pharmaceuticals Inc | Anticancersammensætninger |
| HUP1500055A1 (hu) | 2015-02-09 | 2016-08-29 | Druggability Technologies Ip Holdco Ltd | Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények |
| WO2016162229A1 (fr) * | 2015-04-10 | 2016-10-13 | Capsugel Belgium N.V. | Formulations lipidiques d'acétate d'abiratérone |
| CN108697700B (zh) | 2016-02-04 | 2021-08-17 | 辛多美制药有限公司 | 氘代多潘立酮组合物和用于治疗病症的方法 |
| MX2018009866A (es) | 2016-02-16 | 2018-11-09 | Gx Tech Canada Ltd | Depresor de aleta sustentadora de cinta. |
| SG11201809680QA (en) * | 2016-06-03 | 2018-11-29 | Aragon Pharmaceuticals Inc | Anticancer compositions |
| US11311493B2 (en) * | 2017-04-07 | 2022-04-26 | Maa Laboratories, Inc. | Methods of improving the solubility and bioavailability of therapeutic agents |
| US11364226B2 (en) | 2017-06-30 | 2022-06-21 | Cinrx Pharma, Llc | Deuterated domperidone compositions, methods, and preparation |
| WO2019060525A1 (fr) * | 2017-09-22 | 2019-03-28 | Dispersol Technologies, Llc | Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci |
| US20210008081A1 (en) * | 2018-03-29 | 2021-01-14 | Leiutis Pharmaceuticals Pvt, Ltd | Oral liquid formulations of abiraterone |
| WO2020023017A1 (fr) * | 2018-07-24 | 2020-01-30 | Camx Power, L.L.C. | Additif et procédé de broyage à sec |
| JP2021533194A (ja) | 2018-07-31 | 2021-12-02 | マイクロビオン コーポレーション | ビスマス・チオール組成物及び創傷を治療する方法 |
| HU231297B1 (hu) * | 2018-07-31 | 2022-09-28 | Richter Gedeon Nyrt | Stabil gyógyszerkészítmények és eljárás az előállításukra |
| EP3863918A4 (fr) | 2018-10-09 | 2022-07-20 | GX Technology Canada Ltd. | Système de foils modulaire pour réseau marin remorqué |
| EP3914234A4 (fr) * | 2019-01-25 | 2022-09-14 | Shenzhen Pharmacin Co., Ltd. | Compositions pharmaceutiques |
| US10792292B2 (en) | 2019-03-06 | 2020-10-06 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| CN113133983B (zh) * | 2020-01-20 | 2023-12-12 | 鲁南制药集团股份有限公司 | 一种治疗前列腺癌的药物组合物 |
| EP3944860A1 (fr) | 2020-07-30 | 2022-02-02 | Galenicum Health S.L.U. | Abiratérone pour utilisation dans un procédé de traitement du cancer |
| CN112933053B (zh) * | 2021-01-29 | 2022-11-25 | 中国药科大学 | 一种醋酸阿比特龙的纳米晶体及其制剂和制备方法 |
| CN117120034A (zh) | 2021-02-15 | 2023-11-24 | 普洛佩拉治疗公司 | 阿比特龙前药 |
| US11801252B2 (en) * | 2021-03-05 | 2023-10-31 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition |
| EP4197541A1 (fr) | 2021-12-15 | 2023-06-21 | Hunan Huize Biopharma S&T Co., Ltd | Composition contenant de l'acétate d'abiratérone et son application |
| KR20240010280A (ko) | 2022-07-15 | 2024-01-23 | 한미약품 주식회사 | 아비라테론 아세테이트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478705A (en) | 1994-05-25 | 1995-12-26 | Eastman Kodak Company | Milling a compound useful in imaging elements using polymeric milling media |
| US5500331A (en) | 1994-05-25 | 1996-03-19 | Eastman Kodak Company | Comminution with small particle milling media |
| FR2775188B1 (fr) * | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
| US20050215472A1 (en) * | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| CN104288103B (zh) * | 2006-06-30 | 2019-10-15 | 伊休蒂卡有限公司 | 用于制备纳米粒形式的生物活性化合物的方法 |
| AU2007287098C1 (en) * | 2006-08-25 | 2018-03-15 | Janssen Pharmaceutica Nv | Methods and compositions for treating cancer |
| WO2009009132A1 (fr) * | 2007-07-12 | 2009-01-15 | Cougar Biotechnology, Inc. | Utilisation d'inhibiteurs de 17alpha-hydroxylase/c17,20-lyase pour le traitement du cancer |
| CA2697150A1 (fr) * | 2007-08-17 | 2009-02-26 | Teva Pharmaceutical Industries Ltd. | Procedes et compositions pour controler la biodisponibilite de medicaments faiblement solubles |
| CN103932988A (zh) * | 2009-04-24 | 2014-07-23 | 伊休蒂卡有限公司 | 吲哚美辛的新剂型 |
| NZ595987A (en) * | 2009-04-24 | 2014-02-28 | Iceutica Pty Ltd | A novel formulation of diclofenac |
| CN102740835A (zh) * | 2009-04-24 | 2012-10-17 | 伊休蒂卡有限公司 | 包封的纳米颗粒在工业规模的制备 |
| CA2759109A1 (fr) * | 2009-04-24 | 2010-10-28 | Iceutica Pty Ltd | Une forme de dosage solide de ciprofloxacine ayant des particules de petites taille et des caracteristiques de manipulation de poudre ameliorees |
| CN103764117A (zh) * | 2011-04-15 | 2014-04-30 | 詹森药业有限公司 | 冻干药物纳米混悬剂 |
| WO2013012959A1 (fr) * | 2011-07-18 | 2013-01-24 | Tokai Pharmaceuticals, Inc. | Nouvelles compositions et procédés de traitement du cancer de la prostate |
| GB201207886D0 (en) | 2012-05-04 | 2012-06-20 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2014009436A1 (fr) | 2012-07-11 | 2014-01-16 | Sandoz Ag | Nanosuspension d'acétate d'abiratérone |
| CN102743393A (zh) * | 2012-07-27 | 2012-10-24 | 海南盛科生命科学研究院 | 一种含有醋酸阿比特龙的药物组合物及制备工艺 |
| WO2014083512A1 (fr) * | 2012-11-28 | 2014-06-05 | Dr. Reddy's Laboratories Limited | Procédé de préparation de l'acétate d'abiraterone |
-
2014
- 2014-03-17 CA CA2907415A patent/CA2907415C/fr active Active
- 2014-03-17 BR BR112015023629A patent/BR112015023629A8/pt active Search and Examination
- 2014-03-17 US US14/216,717 patent/US20140287039A1/en not_active Abandoned
- 2014-03-17 SG SG10201709400VA patent/SG10201709400VA/en unknown
- 2014-03-17 AU AU2014232508A patent/AU2014232508C1/en active Active
- 2014-03-17 TW TW103110002A patent/TWI686212B/zh active
- 2014-03-17 WO PCT/US2014/030642 patent/WO2014145813A1/fr active Application Filing
- 2014-03-17 KR KR1020197036996A patent/KR102121404B1/ko active IP Right Grant
- 2014-03-17 JP JP2016503434A patent/JP2016514707A/ja active Pending
- 2014-03-17 SG SG11201507681PA patent/SG11201507681PA/en unknown
- 2014-03-17 NZ NZ712350A patent/NZ712350A/en unknown
- 2014-03-17 TW TW108110818A patent/TWI731321B/zh active
- 2014-03-17 CN CN201910791389.9A patent/CN110604721B/zh active Active
- 2014-03-17 PL PL14765788T patent/PL2969227T3/pl unknown
- 2014-03-17 EP EP14765788.6A patent/EP2969227B1/fr active Active
- 2014-03-17 RU RU2015144285A patent/RU2732136C2/ru active
- 2014-03-17 EP EP19173089.4A patent/EP3578266B1/fr active Active
- 2014-03-17 MX MX2015013247A patent/MX2015013247A/es unknown
- 2014-03-17 KR KR1020157028942A patent/KR20160023641A/ko active Application Filing
- 2014-03-17 CN CN201480028585.6A patent/CN105246598B/zh active Active
- 2014-03-17 ES ES14765788T patent/ES2741800T3/es active Active
- 2014-03-17 KR KR1020187005267A patent/KR20180021932A/ko not_active IP Right Cessation
-
2015
- 2015-08-11 US US14/823,831 patent/US20160067265A1/en not_active Abandoned
- 2015-09-15 CL CL2015002787A patent/CL2015002787A1/es unknown
- 2015-09-16 IL IL241612A patent/IL241612B/en active IP Right Grant
- 2015-09-29 ZA ZA2015/07209A patent/ZA201507209B/en unknown
-
2016
- 2016-06-29 HK HK16107558.1A patent/HK1219457A1/zh unknown
- 2016-07-15 HK HK16108317.1A patent/HK1220162A1/zh unknown
-
2017
- 2017-08-03 US US15/668,387 patent/US20170354665A1/en not_active Abandoned
-
2018
- 2018-04-05 JP JP2018073022A patent/JP2018135351A/ja active Pending
- 2018-10-04 AU AU2018241103A patent/AU2018241103B2/en active Active
-
2020
- 2020-10-28 JP JP2020180136A patent/JP7320485B2/ja active Active
-
2023
- 2023-05-17 JP JP2023081891A patent/JP2023103410A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1220162A1 (zh) | 乙酸阿比特龍酯製劑 | |
| AU353315S (en) | Lounge setting | |
| HK1216839A1 (zh) | 調整釋放製劑 | |
| GB201320432D0 (en) | Novel formulation | |
| HK1223300A1 (zh) | 皮質類固醇組合物 | |
| GB201322948D0 (en) | Improved formulation | |
| HK1214131A1 (zh) | 包含氫化可的松的組合物 | |
| GB2517232B (en) | Formulation | |
| GB201317718D0 (en) | Novel formulation | |
| GB2518724B (en) | Edible formulation | |
| EP2986634A4 (fr) | Formulations de dhea co-cristallines | |
| HK1209981A1 (en) | Formulation | |
| IL243873A0 (en) | Formulation of a saccharide component | |
| HK1211843A1 (en) | Anti-inflammatory agent | |
| GB201312347D0 (en) | Formulation | |
| GB201316663D0 (en) | Edible formulation | |
| AU2013904746A0 (en) | Formulation | |
| AU2013901633A0 (en) | Formulation | |
| GB201317717D0 (en) | Novel formulation | |
| GB201313909D0 (en) | Powder formulation | |
| GB201304146D0 (en) | Powder formulation | |
| GB201304145D0 (en) | Powder formulation | |
| GB201310280D0 (en) | Odontalgic preparation |